Intensity Enterprise Value Over E B I T D A from 2010 to 2025
| INTS Stock | 2.23 0.02 0.90% |
Enterprise Value Over EBITDA | First Reported 2010-12-31 | Previous Quarter (5.84) | Current Value (6.13) | Quarterly Volatility 3.09121437 |
Check Intensity Therapeutics, financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Intensity Therapeutics,'s main balance sheet or income statement drivers, such as Net Interest Income of 26.7 K, Interest Income of 391.2 K or Selling General Administrative of 2.3 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 5.3. Intensity financial statements analysis is a perfect complement when working with Intensity Therapeutics, Valuation or Volatility modules.
Intensity | Enterprise Value Over E B I T D A |
Latest Intensity Therapeutics,'s Enterprise Value Over E B I T D A Growth Pattern
Below is the plot of the Enterprise Value Over E B I T D A of Intensity Therapeutics, Common over the last few years. It is Intensity Therapeutics,'s Enterprise Value Over EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Intensity Therapeutics,'s overall financial position and show how it may be relating to other accounts over time.
| Enterprise Value Over E B I T D A | 10 Years Trend |
|
Enterprise Value Over E B I T D A |
| Timeline |
Intensity Enterprise Value Over E B I T D A Regression Statistics
| Arithmetic Mean | (11.81) | |
| Geometric Mean | 11.32 | |
| Coefficient Of Variation | (26.16) | |
| Mean Deviation | 2.54 | |
| Median | (13.85) | |
| Standard Deviation | 3.09 | |
| Sample Variance | 9.56 | |
| Range | 8.0087 | |
| R-Value | 0.83 | |
| Mean Square Error | 3.12 | |
| R-Squared | 0.69 | |
| Significance | 0.00006 | |
| Slope | 0.54 | |
| Total Sum of Squares | 143.33 |
Intensity Enterprise Value Over E B I T D A History
About Intensity Therapeutics, Financial Statements
Intensity Therapeutics, shareholders use historical fundamental indicators, such as Enterprise Value Over E B I T D A, to determine how well the company is positioned to perform in the future. Although Intensity Therapeutics, investors may analyze each financial statement separately, they are all interrelated. The changes in Intensity Therapeutics,'s assets and liabilities, for example, are also reflected in the revenues and expenses on on Intensity Therapeutics,'s income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Enterprise Value Over EBITDA | (5.84) | (6.13) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Intensity Stock Analysis
When running Intensity Therapeutics,'s price analysis, check to measure Intensity Therapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Intensity Therapeutics, is operating at the current time. Most of Intensity Therapeutics,'s value examination focuses on studying past and present price action to predict the probability of Intensity Therapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Intensity Therapeutics,'s price. Additionally, you may evaluate how the addition of Intensity Therapeutics, to your portfolios can decrease your overall portfolio volatility.